PulmonxLUNG 49 Market Cap is $55.12 Mil as of Jun. 28, 2026. GuruFocus rates LUNG with a GF Score™ of 49/100 and a GF Value™ of $7.13 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 868 Medical Devices & Instruments companies, Pulmonx ranks worse than 60.25% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pulmonx's share price for the quarter that ended in Mar. 2026 was $1.29. Pulmonx's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 42.24 Mil. Therefore, Pulmonx's market cap for the quarter that ended in Mar. 2026 was $54.49 Mil.
Pulmonx's quarterly market cap
increased
from Sep. 2025 ($66.82 Mil) to Dec. 2025 ($92.10 Mil) but then
declined
from Dec. 2025 ($92.10 Mil) to Mar. 2026 ($54.49 Mil).
Pulmonx's annual market cap
declined
from Dec. 2023 ($491.08 Mil) to Dec. 2024 ($270.15 Mil) and
declined
from Dec. 2024 ($270.15 Mil) to Dec. 2025 ($92.10 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pulmonx's Enterprise Value for Today is $49.84 Mil.
Pulmonx (NAS:LUNG) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pulmonx Market Cap Related Terms
Pulmonx Market Cap Historical Data
* Premium members only.
The historical data trend for Pulmonx's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Pulmonx's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulmonx Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Market Cap distribution charts can be found below:
* The bar in red indicates where Pulmonx's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pulmonx's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmonx (LUNG) has a Market Cap of $55.12 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pulmonx and its competitors. According to the industry distribution chart, Pulmonx ranks #523 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 60.3%.
Is Pulmonx's Market Cap too high?
Pulmonx's current Market Cap is $55.12 Mil. The Medical Devices & Instruments industry median Market Cap is 118.39. Pulmonx's value of $55.12 Mil is 53.4% below this industry median. Based on the distribution chart, Pulmonx ranks #523 out of 868 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Market Cap compare to LNSR and QTI?
According to the Medical Devices & Instruments industry distribution chart, Pulmonx ranks #523 out of 868 companies for Market Cap. This places Pulmonx in the lower half of its industry. The industry median Market Cap is 118.39. Pulmonx's value of $55.12 Mil is 53.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 118.39, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulmonx's current Market Cap of $55.12 Mil is 53.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pulmonx and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 118.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulmonx's current Market Cap is $55.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $7.13, compared to a current price of $1.31 — trading 81.7% below its estimated fair value. The current Market Cap is $55.12 Mil and 53.4% below the Medical Devices & Instruments industry median of 118.39. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Pulmonx (LUNG), the current Market Cap is $55.12 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulmonx (LUNG) Overvalued in 2026?
Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued.
The current stock price of $1.31 is trading 81.7% below its estimated GF Value™ of $7.13.
GuruFocus considers Pulmonx to be Possible Value Trap.
Key valuation signals for LUNG:
Market Cap: $55.12 Mil
GF Value™: $7.13 vs. price of $1.31 (81.7% below fair value)
Industry Position: 53.4% below the Medical Devices & Instruments median (#523 of 868)
No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score
Get the complete analysis for LUNG
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUNG has been successfully added to your 
